Comparative Pharmacology
Head-to-head clinical analysis: ASMANEX TWISTHALER versus METICORTELONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASMANEX TWISTHALER versus METICORTELONE.
ASMANEX TWISTHALER vs METICORTELONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators (e.g., cytokines, chemokines, adhesion molecules) and suppression of inflammatory cell migration and activation in the airways.
Corticosteroid with glucocorticoid and mineralocorticoid activity; binds to glucocorticoid receptors, modulating gene expression to suppress inflammation and immune response.
Inhalation: 1-2 inhalations twice daily (morning and evening). Typical adult dose: 200-400 mcg twice daily. Maximum: 800 mcg/day.
Prednisolone: 5-60 mg orally once daily or divided twice daily; methylprednisolone: 4-48 mg orally once daily or divided twice daily. Dose and duration vary by indication.
None Documented
None Documented
The terminal elimination half-life of mometasone furoate following inhalation via ASMANEX TWISTHALER is approximately 5 hours (range 4–6 hours) in patients with asthma. This relatively short half-life supports twice-daily or once-daily dosing with sustained clinical effect due to prolonged local retention in the lungs.
Terminal elimination half-life: 3.0-3.5 hours; clinical context: requires multiple daily doses for sustained effect; biological half-life (duration of HPA suppression) longer (~24-36 hours) due to intracellular activity
Following oral inhalation, the absorbed fraction of mometasone furoate is extensively metabolized in the liver via CYP3A4. Unchanged drug and metabolites are excreted primarily in the feces via biliary elimination (approximately 74% of a single oral dose) and to a minor extent in the urine (approximately 8%). For inhaled doses, renal excretion of unchanged drug is negligible (<1% of administered dose).
Renal: <5% unchanged; hepatic metabolism to inactive metabolites, primarily conjugated and excreted in urine; <2% fecal
Category C
Category C
Corticosteroid, Inhaled
Corticosteroid